ImmunityBio: EMA recommends marketing authorization in EU for ANKTIVA with BCG

ImmunityBio (IBRX) announced that the European Medicines Agency has recommended granting a conditional marketing authorization in the EU for ANKTIVA in combination with Bacillus Calmette-Guerin for the treatment of BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ. This recommendation will help facilitate early access to medicines that address conditions where the remaining treatment option is surgery to remove the bladder. The EMA’s opinion will now be forwarded to the European Commission for final approval of EU-wide marketing authorization.